Skip to main content

Table 3 Determinants of ICU mortality

From: Patterns of ICU admissions and outcomes in patients with solid malignancies over the revolution of cancer treatment

Characteristics

Survivors

Deceased

p

Multivariate analysis

(n = 1180)

(n = 345)

Cause-specific hazard [95% CI]

p

Age (years)

67 [59–75]

68 [60–74]

0.7

  

Male gender

714 (60.5)

230 (66.7)

0.17

  

ICU admission

     

 2007–2012

505 (39.1)

147 (43.6)

0.13

 2013–2018

675 (60.9)

198 (57.4)

 

Type of cancer

  

 < 0.001

  

 Lung

257 (21.8)

122 (35.4)

 Gastrointestinal

298 (25.3)

99 (28.7)

 Urologic

275 (23.3)

39 (11.3)

 Cutaneous

23 (2.0)

3 (0.9)

 Breast

123 (10.4)

30 (8.7)

 Lung cancer

257 (21.8)

122 (35.4)

 < 0.001

1.32 [1.04–1.66]

0.02

 Non-lung cancer

923 (78.2)

223 (64.6)

Stage

  

 < 0.001

  

 Localized

314 (26.6)

58 (16.8)

 Advanced

258 (21.9)

56 (16.2)

 Metastatic

597 (50.6)

227 (65.8)

1.78 [1.38–2.30]

 < 0.001

 Status

  

 < 0.001

  

 Newly diagnosed

314 (26.6)

105 (30.4)

 Partial remission

259 (21.9)

41 (11.9)

 Complete remission

182 (15.4)

38 (11.0)

 In progression

384 (32.5)

156 (45.2)

1.62 [1.28–2.05]

 < 0.001

Treatment in the past 3 months

     

 Chemotherapy

575 (48.7)

181 (52.5)

0.215

 Surgery

183 (15.5)

29 (8.4)

0.003

0.68 [0.45–1.01]

0.05

 Immunotherapy/targeted therapy

129 (10.9)

46 (13.3)

0.256

SOFA score

5 [4–7]

8 [5–12]

 < 0.001

1.02 [1.01–1.03]a

 < 0.001

Organ failure supports

     

 Invasive mechanical ventilation

338 (28.6)

290 (84.1)

 < 0.001

3.73 [2.45–5.69]

 < 0.001

 Non-invasive mechanical ventilation

142 (12.0)

21 (6.1)

0.002

2.87 [1.65–5.01]

 < 0.001

 Inotropes/vasopressors

265 (22.5)

247 (71.6)

 < 0.001

1.74 [1.29–2.34]

 < 0.001

 Renal replacement therapy

144 (12.2)

115 (33.3)

 < 0.001

1.33 [1.03–1.70]

0.03

Admission patterns

     

 Non-specific complications

729 (61.8)

224 (64.9)

0.318

 Specific complications

313 (26.5)

96 (27.8)

0.681

1.33 [1.04–1.72]

0.007

 Adverse event complications

138 (11.7)

25 (7.2)

0.024

 Drug-related adverse event

51 (4.3)

6 (1.7)

0.039

  

 Procedural adverse event

87 (7.4)

19 (5.5)

0.281

  
  1. aThe CSH is related to 1-point increase in the SOFA score